Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Goodwill & Intangibles (2018 - 2022)

Historic Goodwill & Intangibles for Exagen (XGN) over the last 5 years, with Q3 2022 value amounting to $5.5 million.

  • Exagen's Goodwill & Intangibles changed 0.0% to $5.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.5 million for FY2021, which is 0.0% changed from last year.
  • Per Exagen's latest filing, its Goodwill & Intangibles stood at $5.5 million for Q3 2022, which was down 0.0% from $5.5 million recorded in Q2 2022.
  • Exagen's Goodwill & Intangibles' 5-year high stood at $5.5 million during Q4 2018, with a 5-year trough of $5.5 million in Q4 2018.
  • Its 5-year average for Goodwill & Intangibles is $5.5 million, with a median of $5.5 million in 2018.
  • Data for Exagen's Goodwill & Intangibles shows a peak YoY increase of 0.0% (in 2019) and a maximum YoY decrease of 0.0% (in 2019) over the last 5 years.
  • Quarter analysis of 5 years shows Exagen's Goodwill & Intangibles stood at $5.5 million in 2018, then changed by 0.0% to $5.5 million in 2019, then changed by 0.0% to $5.5 million in 2020, then changed by 0.0% to $5.5 million in 2021, then changed by 0.0% to $5.5 million in 2022.
  • Its Goodwill & Intangibles stands at $5.5 million for Q3 2022, versus $5.5 million for Q2 2022 and $5.5 million for Q1 2022.